These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

846 related articles for article (PubMed ID: 33615209)

  • 1. Benefits of early aggressive immunomodulatory therapy (tocilizumab and methylprednisolone) in COVID-19: Single center cohort study of 685 patients.
    Luis BM; Miguel MB; Pedro DL; David IP; Itziar A; Ana GH; Enrique IJ; María LV; Noelia TF; Julio César BB; Marta UI; Rodrigo SL; María CB; Andrés LM; Javier MI; Juan Pablo GM; Gerardo HF; Carolina NF; Jorge BL; María FR; Fernando CT; Sergio OE; Lourdes FC; María GE; Gregoria ML; Adolfo SR; José Antonio FR;
    J Transl Autoimmun; 2021; 4():100086. PubMed ID: 33615209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19.
    Gupta S; Wang W; Hayek SS; Chan L; Mathews KS; Melamed ML; Brenner SK; Leonberg-Yoo A; Schenck EJ; Radbel J; Reiser J; Bansal A; Srivastava A; Zhou Y; Finkel D; Green A; Mallappallil M; Faugno AJ; Zhang J; Velez JCQ; Shaefi S; Parikh CR; Charytan DM; Athavale AM; Friedman AN; Redfern RE; Short SAP; Correa S; Pokharel KK; Admon AJ; Donnelly JP; Gershengorn HB; Douin DJ; Semler MW; Hernán MA; Leaf DE;
    JAMA Intern Med; 2021 Jan; 181(1):41-51. PubMed ID: 33080002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
    Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
    Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia.
    Capra R; De Rossi N; Mattioli F; Romanelli G; Scarpazza C; Sormani MP; Cossi S
    Eur J Intern Med; 2020 Jun; 76():31-35. PubMed ID: 32405160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
    Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
    Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort).
    Guisado-Vasco P; Valderas-Ortega S; Carralón-González MM; Roda-Santacruz A; González-Cortijo L; Sotres-Fernández G; Martí-Ballesteros EM; Luque-Pinilla JM; Almagro-Casado E; La Coma-Lanuza FJ; Barrena-Puertas R; Malo-Benages EJ; Monforte-Gómez MJ; Diez-Munar R; Merino-Lanza E; Comeche-Casanova L; Remirez-de-Esparza-Otero M; Correyero-Plaza M; Recio-Rodríguez M; Rodríguez-López M; Sánchez-Manzano MD; Andreu-Vázquez C; Thuissard-Vasallo IJ; María-Tomé JME; Carnevali-Ruiz D
    EClinicalMedicine; 2020 Nov; 28():100591. PubMed ID: 33078138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital.
    Van den Eynde E; Gasch O; Oliva JC; Prieto E; Calzado S; Gomila A; Machado ML; Falgueras L; Ortonobes S; Morón A; Capilla S; Navarro G; Oristrell J; Cervantes M; Navarro M
    Infect Dis (Lond); 2021 Apr; 53(4):291-302. PubMed ID: 33620019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of COVID-19 pneumonia with glucocorticoids (CORTIVID): a structured summary of a study protocol for a randomised controlled trial.
    Les Bujanda I; Loureiro-Amigo J; Bastons FC; Guerra IE; Sánchez JA; Murgadella-Sancho A; Rey RG; López JL; Álvarez JS
    Trials; 2021 Jan; 22(1):43. PubMed ID: 33430891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab and steroid treatment in patients with COVID-19 pneumonia.
    Mikulska M; Nicolini LA; Signori A; Di Biagio A; Sepulcri C; Russo C; Dettori S; Berruti M; Sormani MP; Giacobbe DR; Vena A; De Maria A; Dentone C; Taramasso L; Mirabella M; Magnasco L; Mora S; Delfino E; Toscanini F; Balletto E; Alessandrini AI; Baldi F; Briano F; Camera M; Dodi F; Ferrazin A; Labate L; Mazzarello G; Pincino R; Portunato F; Tutino S; Barisione E; Bruzzone B; Orsi A; Schenone E; Rosseti N; Sasso E; Da Rin G; Pelosi P; Beltramini S; Giacomini M; Icardi G; Gratarola A; Bassetti M
    PLoS One; 2020; 15(8):e0237831. PubMed ID: 32817707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefits of Tocilizumab in patients with a severe form of SARS-CoV-2 infection: Experience of the intensive care unit of the Mohammed VI university hospital, Oujda.
    El Rhalete A; Rhazi I; Bensaid A; Diass S; Kaouini A; Ounci E; Abdi M; Maarad M; Babouh C; Alami Z; Abda N; Bkiyer H; Housni B
    Ann Med Surg (Lond); 2021 Jul; 67():102514. PubMed ID: 34221397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocilizumab for severe COVID-19 pneumonia: Case series of 5 Australian patients.
    West TA; Malik S; Nalpantidis A; Tran T; Cannon C; Bhonagiri D; Chan K; Cheong E; Wan Sai Cheong J; Cheung W; Choudhury F; Ernest D; Farah CS; Fernando S; Kanapathipillai R; Kol M; Murfin B; Naqvi H; Shah A; Wagh A; Ojaimi S; Frankum B; Riminton S; Keat K
    Int J Rheum Dis; 2020 Aug; 23(8):1030-1039. PubMed ID: 32881350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mortality comparison between the first and second/third waves among 3,795 critical COVID-19 patients with pneumonia admitted to the ICU: A multicentre retrospective cohort study.
    Carbonell R; Urgelés S; Rodríguez A; Bodí M; Martín-Loeches I; Solé-Violán J; Díaz E; Gómez J; Trefler S; Vallverdú M; Murcia J; Albaya A; Loza A; Socias L; Ballesteros JC; Papiol E; Viña L; Sancho S; Nieto M; Lorente MDC; Badallo O; Fraile V; Arméstar F; Estella A; Sanchez L; Sancho I; Margarit A; Moreno G;
    Lancet Reg Health Eur; 2021 Dec; 11():100243. PubMed ID: 34751263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous methylprednisolone with or without tocilizumab in patients with severe COVID-19 pneumonia requiring oxygen support: A prospective comparison.
    Hamed DM; Belhoul KM; Al Maazmi NA; Ghayoor F; Moin M; Al Suwaidi M; Narainen M; Makki M; AbdulRahman M
    J Infect Public Health; 2021 Aug; 14(8):985-989. PubMed ID: 34153729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Methylprednisolone on Ventilator-Free Days in Mechanically Ventilated Patients with Acute Respiratory Distress Syndrome and COVID-19: A Retrospective Study.
    Badr M; De Oliveira B; Abdallah K; Nadeem A; Varghese Y; Munde D; Salam S; Abduljawad B; Saleh K; Elkambergy H; Taha A; Bayrlee A; Wahla A; Dibu J; Haque R; Hamed F; Rahman N; Mallat J
    J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33672805
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 43.